Thank you, STAT, for another great summit! Our team enjoyed hearing from some of the top voices in the industry, as well as policymakers and advocates. We were proud to sponsor this year’s event and have our Chief Medical Officer, Dr. Steven O'Day, share his insights on cancer #immunotherapy. #STATSummit
About us
Agenus is a leading immuno-oncology company targeting cancer and infectious diseases with a comprehensive pipeline of immunological agents. The company’s mission is to expand patient populations benefiting from cancer immunotherapy through combination approaches, using a broad repertoire of antibody therapeutics, adoptive cell therapies (through MiNK Therapeutics) and adjuvants (through SaponiQx). Agenus is headquartered in Lexington, MA. For more information, visit www.agenusbio.com or follow us at @agenus_bio. Our Community Guidelines are available at our website and at: https://agenusbio.com/community-guidelines/
- Website
-
https://agenusbio.com/.
External link for Agenus
- Industry
- Biotechnology Research
- Company size
- 201-500 employees
- Headquarters
- Lexington, Massachusetts
- Type
- Public Company
- Founded
- 1994
- Specialties
- Immuno-oncology, Cancer Vaccines, Checkpoint Inhibitors and Modulators, Immunotherapy, Cell therapy, Antibodies, and GMP Manufacturing
Locations
-
Primary
3 Forbes Road
Lexington, Massachusetts 02421, US
Employees at Agenus
-
Brian Greenblatt
-
Doreene Burke
Head of Global Supply Chain at Agenus
-
Tracy Clemente
Chief Human Resources Officer @ Agenus
-
Bob Durham, Designing Destination Health Intel
We promote Medical Travel Revenues with Top-Level Destinations by taking advantage of Destination Health Intelligence!
Updates
-
Agenus has arrived at the #STATSummit! We’re looking forward to Dr. Steven O'Day’s Eureka Moment talk: “Rethinking How We Measure Cancer Immunotherapies,” which will explore how traditional metrics of tumor response often fail to capture the full benefits cancer #immunotherapy can provide.
-
We’re on a mission to harness the power of the immune system to bring therapies to individuals living with #cancer. Celebrate 30 years of innovation with us and learn more about our history: https://bit.ly/47mOYw4
-
We’re excited to congratulate our Chairman & CEO, Dr. Garo Armen, on receiving WITSA’s Eminent Person Award. This recognition is a testament to his leadership and commitment to advancing #immunotherapy. We’re grateful to WITSA for honoring the impact his work continues to have on improving patients’ lives.
-
We’ll be attending the Society for Immunotherapy of Cancer (SITC)’s 39th Annual Meeting in Houston, TX next month! We look forward to connecting with researchers, clinicians, and other industry leaders driving #immunotherapy R&D. https://lnkd.in/ggphnMEm #SITC24
-
The National Breast Cancer Foundation, Inc. reports that more than 360,000 people will be diagnosed with breast cancer in 2024. This #BreastCancerAwarenessMonth and every month, we support efforts to advance early detection methods and innovative treatment options that can help increase chances of survival.
-
We’re proud to sponsor this year’s #STATSummit, focused on delivering meaningful impacts in health and medicine and bringing breakthroughs to patients — all while convening decision makers in one place. Our Chief Medical Officer, Dr. Steven O'Day, will be sharing his insights during his talk, “Rethinking How We Measure Cancer Immunotherapies.” #Immunotherapy
-
This #WorldCancerResearchDay, we are proud to support advocacy groups like the Colorectal Cancer Alliance that work to empower patients, families, caregivers, and survivors. Learn more about how you can support their research efforts! 👇
Today is World Cancer Research Day. Colorectal cancer is the 2nd leading cause of cancer deaths overall, yet research into the disease is less funded than other less-deadly cancers. Together, we can change this. Project Cure CRC, the Alliance’s new research fund, has received over 100 proposals. With $3.5 million awarded this year, your donation could further the project’s potential for breakthroughs in colorectal cancer. Rapid advances in science and research are crucial in developing better treatments to help today’s patients who have run out of other options. You can drive progress in science and research through your gift to the Alliance today. Your donation this World Cancer Research Day will also make a real difference by supporting CRC patients through access to: 👉 Education and advocacy around biomarker testing to improve treatment options 👉 A colorectal cancer clinical trial search tool on our website 👉 Patient and family navigators who help patients understand and move forward with a treatment plan best for them. By funding these essential programs, you are ensuring that strides to prevent and treat colorectal cancer continue to be made. Thank you for coming together with other donors to help reach a $100,000 fundraising goal by September 30 to fund these critical programs. Please consider a donation — your gift will provide hope and help save lives. Thank you for your generosity in honor of World Cancer Research Day. Make a gift 👉 https://lnkd.in/eXejmvhR #WCRD #WorldCancerResearchDay #WCRD24
-
Today, Breelyn Wilky, MD, presented new data at #ESMO24 highlighting the potential of our investigational immunotherapy combination, botensilimab and balstilimab, for treating patients with refractory sarcomas. Learn more about this advancement: https://bit.ly/4d4g0cH